New York – Federal Court Upholds Patenting on Human Genes

    8

    New York – A federal court said that human genes can be patented, reversing a lower court’s ruling that involved a test for breast cancer but which could have hurt research and profits for drugmakers and agriculture companies.

    Join our WhatsApp group

    Subscribe to our Daily Roundup Email


    Judge Alan Lourie’s ruling says the genes can be patented because the isolated DNA has a “markedly different chemical structure” from DNA within the body. The U.S. Patent and Trademark Office has been awarding patents on human genes for almost 30 years.

    “The ability to visualize a DNA molecule through a microscope, or by any other means, when it is bonded to other genetic material, is worlds apart from possessing an isolated DNA molecule that is in hand and usable,” Lourie wrote for a 2-to-1 majority. “It is the difference between knowledge of nature and reducing a portion of nature to concrete form, the latter activity being what the patent laws seek to encourage and protect.”

    The lawsuit concerned two patents held by Myriad Genetics Inc. of Salt Lake City. Myriad’s BRACAnalysis test looks for mutations on the breast cancer predisposition gene, or BRCA. Those mutations are associated with much greater risks of breast and ovarian cancer. The American Civil Liberties Union argued that genes couldn’t be patented, and in March 2010, a New York district court agreed.

    “Today’s ruling is a blow to the idea that patent law cannot impede the free flow of ideas in scientific research,” said Chris Hansen, a staff attorney with the ACLU Speech, Privacy and Technology Project.

    ACLU Attorney Sandra Park said the ACLU will consult with its clients to decide whether to appeal or seek another remedy. The plaintiffs include geneticists who said they were not able to continue their work because of Myriad’s patents, along with breast cancer and women’s health groups, patients, and groups of researchers, pathologists, and laboratory professionals.

    Myriad was able to continue selling the BRACAnalysis test despite the previous ruling from Judge Robert Sweet of the U.S. District Court for the Southern District of New York.

    Lourie ruled against Myriad on five claims, saying the company cannot patent comparisons and analysis of DNA sequences. The company said it still holds 237 claims that are not affected by the decision. The company’s shares rose 2.3 percent in aftermarket trading.


    Listen to the VINnews podcast on:

    iTunes | Spotify | Google Podcasts | Stitcher | Podbean | Amazon

    Follow VINnews for Breaking News Updates


    Connect with VINnews

    Join our WhatsApp group


    8 Comments
    Most Voted
    Newest Oldest
    Inline Feedbacks
    View all comments
    Pereles
    Pereles
    12 years ago

    from where (or whom) do they get the genes in the first place? Not sure how this works, but I’m thinking that if people are donating their cells, shouldn’t everyone else benefit without huge profits for the pharmaceuticals? Just asking, although I don’t fully understand the concept…

    Rabbi Yair Hoffman
    Admin
    12 years ago

    Can G-d be sued for breaching the patent. If so, can the various houses of G-d in each religious domination be taken in payment?

    acomment
    acomment
    12 years ago

    And when the gene is found in a person, do they own them too?

    Darth_Zeidah
    Darth_Zeidah
    12 years ago

    Now what leads me to think that comment #3 and comment #4 came from the same (anonymous) contributor?

    ComeOn
    ComeOn
    12 years ago

    Anything that is bad for the ACLU is good for America.